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Introduction 
Prostate cancer (PCa) is the commonest male cancer as well as the second 
leading cause of cancer death in men.1 The standard cancer screening protocol 
includes serum prostate specific antigen (PSA) testing and digital rectal 
examination (DRE). If either are abnormal, prostate biopsy with subsequent 
histopathologic evaluation represents the gold standard for establishing the 
diagnosis.2 Prostate biopsy can be performed either by the more traditional 
transrectal approach or by the increasingly popular transperineal route, using a 
transrectal ultrasound probe for needle guidance. In both methods, rectal access 
is essential. Abdominoperineal resection (APR) is a common surgical technique 
performed in a selected group of patients with inflammatory bowel disease (IBD), 
carcinoma of the distal rectum or anal canal and familial adenomatous polyposis 
(FAP). It involves resection of the distal part of the sigmoid colon, rectum, anus 
and the creation of a permanent end-colostomy.3 As life expectancy in patients 
with IBD and FAP is not significantly lower than that of the general population 
and the 5-year-survival rate in stage T1 and T2 colorectal tumours treated with 
APR was found to be 78%, it is not uncommon to encounter post-APR patients 
presenting with a raised PSA and suspicion of prostate cancer.4 The lack of 
rectal access means that such patients pose a diagnostic challenge. 
Previously described diagnostic approaches in this cohort include biopsy by 
either a transperineal or transgluteal approach and under the guidance of 
ultrasound (transperineal, transabdominal or transurethral), magnetic resonance 
imaging (MRI) or computed tomography (CT). 5-14 Cancer detection rates ranged 
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from 40 - 82 %,7-14 but even in the largest cohort, detection of intermediate to 
high grade prostate cancer (Gleason score ≥7) was low at 43%.12 However, all 
studies to date have used a systematic biopsy approach and did not use MRI 
prior to biopsy to target suspicious areas. 
Recently, multi-parametric Magnetic Resonance Imaging (mpMRI) has been 
shown to be effective for the detection and local staging of prostate cancer and 
can preferentially detect clinically relevant index tumours of higher grade and a 
size >5 mm.15 A normal mpMRI also has a high negative predictive (>90%) for 
the presence  of clinically significant disease.16 Using transperineal MR/US fusion 
biopsy, the detection rate for clinically significant disease  has been shown to be 
as high as 72%.17 The aim of this study was to evaluate if the use of 
multiparametric MRI and subsequent cognitively targeted US-guided (by visual 
registration) transperineal biopsy improves cancer detection and particularly 
detection of significant cancer in patients with abdominoperineal resection and a 
suspicion of prostate cancer. 
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Patients and Methods 
Study population 
This single-institution retrospective study was part of a service evaluation of 
transperineal prostate biopsies with the need for informed consent for data 
analysis waived by the local ethics committee (Local audit evaluation number 
4058). The study population consisted of 11 consecutive patients who presented 
to our institution between March 2010 and May 2015 with elevated PSA, a 
history of abdominoperineal resection of the rectum and undergoing prostate MRI 
at our institution prior to biopsy.  
 
Magnetic resonance imaging 
Patients underwent prostate MRI on a 1.5T MR450 or 3.0T Discovery MR750 
HDx (GE Healthcare, Waukesha, USA) with an 8-16 channel surface phased 
array coil. Axial Fast Spin Echo T1-weighted images of the pelvis, along with T2-
Weighted Fast Recovery Fast Spin Echo images of the prostate were acquired in 
the axial, sagittal and coronal planes (TE/TR = 85/3700-5000 ms; field-of-view 
(FOV) 24x24 cm; matrix 256x256; slice thickness 3 mm; gap 1 mm). Diffusion-
weighted (DW) imaging was performed using a spin-echo echo-planar imaging 
pulse sequence (TE/TR=60/3000-3400 ms; matrix 256x256; slice thickness 4 
mm; gap 0 mm, FOV: 1.5T: 24x24 cm, 3.0T: 28x28 cm; parallel imaging factor of 
2; signal averages: 3 for 1.5T and 8 for 3.0T. The following b-values were 
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acquired: b-150, b-750, b-1,400 s/mm2; apparent diffusion coefficient (ADC) 
maps were automatically calculated and stored. 
 
Image analysis 
The MR images were prospectively reported by body radiologists experienced in 
reading prostate MRI. T2WI and DWI sequences were evaluated using a Likert 
scale of tumour probability, based on the Prostate Imaging Reporting and Data 
System (PI-RADS) structured scoring criteria developed by the European Society 
of Urogenital Radiology (ESUR).18 The Likert-based scoring system was as 
follows: 1 =  cancer highly unlikely, 2 =  cancer unlikely, 3 =  indeterminate for 
cancer, 4 =  cancer likely, 5 =  cancer highly likely. A positive MRI was defined as 
a score of ≥ 3. The location of the lesion was communicated in the report 
descriptively for earlier cases, and subsequently using the standardized sector 
map first proposed by Dickinson et al.19 
 
Biopsy 
Patients with a Likert score of 3-5 underwent transperineal ultrasound-guided 
biopsies under general anaesthesia. Transperineal biopsies were performed by a 
urologist (XX) with 29 years experience in prostate biopsy and 8 years 
experience in transperineal biopsy. The procedure was performed using 
transperineal ultrasound-guidance from one of two experienced radiologists (XX, 
XX). Each patient was placed in the lithotomy position, with the scrotum retracted 
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anteriorly. Bladder filling was not routinely employed as a transvesicular imaging 
plane was not chosen.  
 
All ultrasound scanning was performed on a Toshiba Aplio 500 machine (Toshiba 
Medical Systems, UK) using a curved linear array ultrasound transducer with a 
centre frequency of 3.5MHz, range 1.9-6 MHz. The transducer was enclosed in a 
rubber sheath with sterilised ultrasound gel for transmission. Direct contact was 
made to the skin in the midline sagittal plane, to allow lateral transperineal needle 
access (Figure 1). Biopsies were obtained using an automatic spring driven 
biopsy device mounted with an 18-gauge biopsy needle (Bard biopsy systems, 
Tempe, USA) via a caudal approach to the prostate. The needle was directed to 
target areas by visual registration and systematically to background prostate by 
the operator, with position confirmed on US prior to sampling (Figure 2).  
  
Histopathology  
Biopsies were reviewed by a single sub-specialist uropathologist. Each core was 
measured, and the total number of cores with cancer and the percentage of 
cancer recorded. Pathology reports identified the Gleason Score for each side of 
the prostate, and the target.  
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Results 
11 men with a median age of 68 years (range 63 - 77 years) were included with a 
median PSA of 9.4 ng/ml (mean 13.6; range 3.2 - 60 ng/mL); Table 1. The mean 
prostate volume was 37.8 ml (median 35; range 24 - 49 ml). Abdominoperineal 
resection had been performed for ulcerative colitis (7 patients), Crohn’s disease, 
Hereditary nonpolyposis colorectal cancer, rectal carcinoma, and Canada-
Cronkheit syndrome. The mean interval from MRI to biopsy was 57.6 days 
(range 22 - 106 days).  
 
Transperineal ultrasound guided biopsies were successfully completed in 9 
cases. On average 16.7 (range 11 - 27) biopsy cores with a median of 5 (range 
3-7) target cores were obtained under ultrasound guidance. All patients 
undergoing biopsy were discharged on the day of procedure, 2/9 patients 
experienced acute urinary retention after biopsy, 1 described mild perineal 
discomfort, the other 6 had no ill effects. Of the 9 biopsies performed, 7 (78%) 
revealed prostate cancer with a Gleason score ranging from 6 - 10. 6/9 (67%) 
cases revealed a Gleason score of  ≥7, 1/9 cases (11%) revealed a Gleason 
score of 6. Median cancer core length was 2 mm (range 1 - 19mm). Treatment 
choices in patients with confirmed prostate cancer included open radical 
prostatectomy in 2 patients, external beam radiation therapy in 2, active 
surveillance in 2, and androgen deprivation therapy in 1.  
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9 patients exhibited suspicious lesions on MRI (Figure 2). Five patients had 
suspicious lesions in the posterior peripheral zone and four patients in the 
anterior transition zone. The median lesion diameter was 15 mm (range 7-25 
mm). All 7 patients with highly suspicious lesions (Likert 4-5) on MRI had 
subsequent biopsy-proven tumour: 6 cases revealed Gleason score ≥7 cancer, 
with 1 case of Gleason grade 3+3. Biopsies from the target and adjacent area did 
more often contain cancer than background cores with higher number of positive 
cores in all seven cases, higher percentages of cancer involvement in all seven 
cases and/or higher Gleason scores in five cases. 
 
The 2 cases with MR lesions of an intermediate probability score of 3/5 revealed 
benign tissue at biopsy. Two patients with a negative MRI did not undergo 
biopsy. The 4 patients with no histological diagnosis of prostate cancer had 
stable PSA levels at follow-up, with PSA-monitoring performed at 3 months for 
one year and 6-monthly thereafter; mean follow-up 17.5 months (range 7 - 28 
months) 
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Comment 
Our study shows that multiparametric prostate MRI is feasible and useful for 
targeted transperineal biopsy guided by visual registration in patients with 
abdominoperineal resection and a suspicion of prostate cancer. The overall 
cancer detection rate was 7/9 (78%) with 6/9 (67%) cases demonstrating a 
Gleason score of 7 or higher. This compares favourably to previously published 
studies without prior MRI, reporting overall cancer detection rates of 20% (2 of 10 
patients), 40% (2/5), 43% (3/7), 60% (6/10) and 82 % (23/28).7-10,12 It has 
previously been shown that pre-biopsy MR imaging increases biopsy 
performance in detecting prostate cancer and especially clinically significant 
cancer, via both a transperineal and transrectal approach using MR/US fusion 
techniques.17,20 Although our high detection rate of clinically significant cancers 
may partially be explained by patients without rectal access presenting with 
larger and more significant cancers due a delayed diagnosis,20 our detection rate 
of 67% for Gleason score ≥7 disease is notably higher than any of the equivalent 
series that have previously been reported.  
 
Our data suggests that patients with abdominoperineal resection benefit from a 
pre-biopsy multiparametric MRI and, in the case of suspicious lesions with a 
Likert score of 4-5, should undergo targeted transperineal biopsy guided by 
visual registration. In our study population, 6/7 cases with highly suspicious MRI 
lesions (Likert 4-5) revealed clinically significant adenocarcinomas with a 
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Gleason score of 7 or higher, with 1 case of low-risk Gleason score 6 prostate 
cancer. The results are in accordance with a meta-analysis of patients with rectal 
access undergoing MRI prior to initial targeted biopsy of the prostate with an 
overall detection rate of 65% for prostate cancer and 49% for significant 
disease.21 Additionally, a recent study using targeted transperineal biopsy with 
rectal access for MR/US fusion found that 85% (89/104) of patients with highly 
suspicious lesions on MRI were diagnosed with prostate cancer in the biopsy, 
including 60% (62/104) with high risk cancer of GS of 7 or greater.17 A fusion 
approach is not possible in the setting of prior APR and image guidance by visual 
registration despite its operator-dependence is the only means of biopsy 
targeting. Previous studies have reported contradicting results when comparing 
visually-registered and software-registered MR/US fusion targeted transrectal 
biopsies after prebiopsy MRI: with one demonstrating equivalence,20 another 
showing increased detection with software-registration biopsy, especially for 
smaller lesions,22 and a third, larger study, concluding that software-registration 
biopsy was more histologically informative but did not increase cancer 
detection.23 An alternative to biopsies guided by visual estimation would be real-
time in-bore MRI-targeted biopsies, via a transperineal or transgluteal 
approach,24,25however, this is cost- and time-intensive, requires special MR-safe 
equipment, and  is not available at all centers. In our study, the 2 cases with 
Likert 3 MR lesions revealed benign tissue upon biopsy. It may therefore be 
possible to avoid biopsy in patients with intermediate risk MRI, but this is a 
controversial area. Previous studies in patients without APR, showed a yield of 
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any cancer of 20-25% in intermediate probability cases, although typically the 
majority of these are low risk cancers.26,27 
 
A limitation of our study is its retrospective nature and the small population size, 
especially the patients without suspicious lesions on MRI. The lack of 
prostatectomy as a gold standard in all but two patients is also a limitation, and 
we therefore cannot exclude some smaller tumours being missed. Another 
limitation of MRI –targeted transperineal biopsies guided by visual registration is 
the difficulty of ultrasound guidance. Needle visualisation can be challenging due 
to lateral entry point of the needle to the ultrasound probe and the off-plane 
trajectory taken, additionally the beam may be scattered by the fibromuscular 
layers of the pelvic floor or surgery-related scarring. Theoretically these effects 
could be exacerbated in glands with larger volume, more heterogeneous 
transition zone, however, significant BPH was not present in our cohort (gland 
volume 24 - 49 ml). Patient body mass index (BMI) is less likely to have an affect 
given the transperineal approach. Steps taken to improve visualisation included 
small movements of the needle to ascertain position indirectly through tissue 
motion, incremental tilting and rotation of the probe to change beam position, or 
even switching to the transverse plane (Figure 3). Although not employed here, 
consideration could also be given to catheterisation to aid urethral land-marking 
and help establish the prostatic midpoint. 
 
We describe the first use of MRI to aid targeting of prostate biopsies in patients 
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post APR, with the approach achieving promising results in this challenging 
patient group. Our findings could also be extended to the group of patients with 
ileal pouch/anal anastomosis, where transpouch biopsy of the prostate may risk 
pouch fistulas or abscesses.28-30 
 
Conclusions 
In conclusion, the use of multiparametric prostate MRI and subsequent targeted 
transperineal biopsy guided by visual registration can aid in the diagnostic 
pathway of patients with abdominoperineal resection and a suspicion of prostate 
cancer. 
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Legends to illustrations 
 
Fig. 1 Transperineal ultrasound views 
A: ultrasound image in the sagittal (longitudinal) plane. B: sagittal T2-weighted 
MR image at the same level. PZ = peripheral zone of prostate; TZ = transition 
zone; CS = corpus spongiosum; Bl = bladder; P = pubic bone 
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Fig. 2 High probability MRI target 
66 year old patient with PSA 11.74 ng/ml and previous total colectomy for 
Canada-Cronkhite syndrome. A-C: MRI shows a high probability 2.5 cm lesion in 
the anterior right base transition zone (*) with low T2 signal intensity (A) and 
restricted diffusion with high signal on the b-1400 images (B) and low ADC value 
(C). D: Sagittal plane ultrasound image of transperineal biopsy needle (arrow) 
guided to this region. Subsequent pathology confirmed Gleason 4+3 disease 
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Fig. 3 Ultrasound biopsy guidance: Switching to coronal plane for needle 
visualisation 
68 year old patient with PSA 3.2 ng/ml and strong family history of prostate 
cancer and low probability MRI. A: Ultrasound switched to coronal (transverse) 
plane to aid needle visualisation (arrow). B: Coronal T2-weighted MR image at 
an equivalent position 
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Tables 
Table 1 Results for patients who underwent transperineal prostate biopsy listed in order of date of procedure  
Patient 
Age 
(year
s) 
Indication 
for 
anorectal 
resection 
Time 
since 
resecti
on 
(years) 
PSA 
(ng/
mL) 
Volu
me 
(mL) 
PSA 
Dens
ity 
(ng/
mL/
mL) 
MRI 
results 
Max 
Lesion 
diamete
r (mm) 
Interval 
MRI to 
biopsy 
(days) 
Number 
of Cores 
(n) 
Number 
of 
positive 
Cores 
(n) 
CCL 
(mm) 
Biopsy 
Result 
(Gleason 
score) Management 
1 72 UC 22 60 28 2.14 + 15 22 11 3 3 5+5 ADT 
2 77 Rectal Ca 5 15.7 31 0.51 + 16 70 19 6 10 3+5 EBRT 
3 77 UC 2 14.8 45 0.33 
+ 14 
34 13 1 
1 
4+3 
Neoadjuvant ADT, 
EBRT 
4 65 UC 43 5.2 24 0.22 + 10 106 12 2 1 3+3 AS 
5 65 UC n/a 7.1 26 0.27 + 9 58 27 0  Benign PSA Follow-up, stable 
6 66 CCS 30 11.7 34 0.35 + 25 83 16 5 2 3+4 AS 
7 63 HNPCC 14 3.2 49 0.07 + 7 68 21 0  Benign PSA Follow-up, stable  
8 70 UC  7 9.4 44 0.21 
+ 15 
43 13 5 
2 
4+5 
Neoadj ADT, 
prostatectomy 
9 65 UC 25 3.9 35 0.11 + 16 34 18 12 19 4+5 prostatectomy 
10 68 Crohn’s 40 8.8 59 0.15 -       PSA Follow-up, stable  
11 68 UC 6 9.6 41 0.23 -       PSA Follow-up, stable  
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HNPCC = Hereditary nonpolyposis colorectal cancer, UC = ulcerative colitis, CCS = Canada-Cronkheit syndrome, AS = 
active surveillance, ADT = androgen deprivation therapy, Gl = Gleason, EBRT = external beam radiotherapy, PSA = 
prostate specific antigen 
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